Fonseca Maria Inês Pires, Pereira Telmo, Caseiro Paulo
Departamento de Fisiologia Clínica, Instituto Politécnico de Coimbra, Coimbra, Portugal.
Arq Bras Cardiol. 2015 Jan;104(1):58-66. doi: 10.5935/abc.20140172. Epub 2014 Nov 18.
Several studies have been attempting to ascertain the risks of Sleep Apnea Syndrome (SAS) and its morbidity and mortality.
The main objective was to verify whether SAS increases the risk of death; the secondary objective was to evaluate its morbidity in relation to cardiovascular disease and the number of days hospitalized.
A systematic review and a meta-analysis were performed of the published literature. The research focused on studies comparing the number of deaths in patients with untreated SAS and in patients with non-SAS.
The meta-analysis was based on 13 articles, corresponding to a total of 13394 participants divided into two groups (non-SAS = 6631; SAS = 6763). The meta-analysis revealed a clear association of SAS with the occurrence of fatal events, where the presence of SAS corresponded to a 61% higher risk of total mortality (OR=1.61; CI: 1.43 - 1.81; p < 0.00001), while the risk of death from cardiac causes was 2.52 times higher in these patients (OR = 2.52; IC: 1.80 - 3.52; p < 0.00001). Similar results were obtained for mortality from other causes (OR = 1.68; CI: 1.08 - 2.61; p = 0.02). Resembling results were obtained in the remaining outcomes: non-fatal cardiovascular events were higher in the SAS group (OR = 2.46; IC: 1.80 - 3.36; p < 0.00001), the average number of days hospitalized was also higher in the SAS group (IV = 18.09; IC: 13.34 - 22.84; p < 0.00001).
The results show that untreated SAS significantly increases the risk of death, cardiovascular events and the average number of days hospitalized.
多项研究一直在试图确定睡眠呼吸暂停综合征(SAS)的风险及其发病率和死亡率。
主要目的是验证SAS是否会增加死亡风险;次要目的是评估其与心血管疾病相关的发病率以及住院天数。
对已发表的文献进行了系统综述和荟萃分析。该研究聚焦于比较未经治疗的SAS患者和非SAS患者的死亡人数的研究。
荟萃分析基于13篇文章,总共13394名参与者被分为两组(非SAS组 = 6631人;SAS组 = 6763人)。荟萃分析显示SAS与致命事件的发生存在明显关联,其中SAS的存在对应总死亡率高61%(OR = 1.61;CI:1.43 - 1.81;p < 0.00001),而这些患者因心脏原因死亡的风险高2.52倍(OR = 2.52;IC:1.80 - 3.52;p < 0.00001)。其他原因导致的死亡率也得到了类似结果(OR = 1.68;CI:1.08 - 2.61;p = 0.02)。在其余结果中也得到了类似结果:SAS组的非致命心血管事件更高(OR = 2.46;IC:1.80 - 3.36;p < 0.00001),SAS组的平均住院天数也更高(IV = 18.09;IC:13.34 - 22.84;p < 0.00001)。
结果表明,未经治疗的SAS会显著增加死亡风险、心血管事件风险和平均住院天数。